Short Interest in Cingulate Inc. (NASDAQ:CINGW) Rises By 405.4%

Cingulate Inc. (NASDAQ:CINGW) was the recipient of a significant growth in short interest during the month of April. As of April 30th, there was short interest totaling 11,190 shares, a growth of 405.4% from the April 15th total of 2,214 shares. Based on an average daily volume of 15,395 shares, the short-interest ratio is presently 0.7 days.

Cingulate Price Performance

NASDAQ:CINGW opened at $0.02 on Wednesday. Cingulate has a 1-year low of $0.02 and a 1-year high of $0.18. The firm has a fifty day simple moving average of $0.03 and a 200 day simple moving average of $0.05.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.